- Home
- LNKB vs ACIU Comparison
LNKB vs ACIU Comparison
Compare LNKB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- ACIU
- Stock Information
- Founded
- LNKB 2018
- ACIU 2003
- Country
- LNKB United States
- ACIU Switzerland
- Employees
- LNKB N/A
- ACIU N/A
- Industry
- LNKB
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- ACIU Health Care
- Exchange
- LNKB Nasdaq
- ACIU Nasdaq
- Market Cap
- LNKB 261.4M
- ACIU 213.3M
- IPO Year
- LNKB N/A
- ACIU 2016
- Fundamental
- Price
- LNKB $7.14
- ACIU $2.86
- Analyst Decision
- LNKB Strong Buy
- ACIU Strong Buy
- Analyst Count
- LNKB 1
- ACIU 2
- Target Price
- LNKB $9.00
- ACIU $10.00
- AVG Volume (30 Days)
- LNKB 118.6K
- ACIU 345.6K
- Earning Date
- LNKB 10-27-2025
- ACIU 11-04-2025
- Dividend Yield
- LNKB 4.19%
- ACIU N/A
- EPS Growth
- LNKB 512.12
- ACIU N/A
- EPS
- LNKB 1.03
- ACIU N/A
- Revenue
- LNKB $122,594,000.00
- ACIU $5,482,957.00
- Revenue This Year
- LNKB $18.38
- ACIU N/A
- Revenue Next Year
- LNKB N/A
- ACIU $1,022.98
- P/E Ratio
- LNKB $6.97
- ACIU N/A
- Revenue Growth
- LNKB 42.32
- ACIU N/A
- 52 Week Low
- LNKB $6.09
- ACIU $1.43
- 52 Week High
- LNKB $7.98
- ACIU $4.00
- Technical
- Relative Strength Index (RSI)
- LNKB 48.19
- ACIU 40.94
- Support Level
- LNKB $7.14
- ACIU $3.20
- Resistance Level
- LNKB $7.75
- ACIU $3.23
- Average True Range (ATR)
- LNKB 0.23
- ACIU 0.26
- MACD
- LNKB -0.01
- ACIU -0.07
- Stochastic Oscillator
- LNKB 25.00
- ACIU 1.18
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.